Date: 2011-08-29
Type of information: R&D agreement
Compound: small molecule lead candidates
Company: NovAliX (France) Galapagos (Belgium)
Therapeutic area: Rheumatic diseases - Inflammatory diseases – Bone diseases
Type agreement: research - R&D
Action mechanism:
Disease: osteoarthritis
Details: NovAliX has entered into drug discovery collaboration in the field of osteoarthritis with Galapagos. Under the terms of this agreement NovAliX will be responsible for the discovery of specific small molecule lead candidates for a novel, validated osteoarthritis target chosen by Galapagos. NovAliX will identify hits using its Graffinity fragment-based screening technology that combines chemical micro-arrays with a proprietary SPR-imaging method for the detection of compound-protein interactions and then further progress this program to the lead candidate stage by applying its medicinal chemistry and structural biology expertise.
Financial terms: NovAliX will receive technology access fees, research funding and is eligible to receive success-based milestones from Galapagos.
Latest news:
